Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Ancans, J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front. Immunol. 3, 253 (2012).
Yin, J. Q., Zhu, J. & Ankrum, J. A. Manufacturing of primed mesenchymal stromal cells for therapy. Nat. Biomed. Eng. 3, 90–104 (2019).
O’Brien, T. & Barry, F. P. Stem cell therapy and regenerative medicine. Mayo Clin. Proc. 84, 859–861 (2009).
Mousaei Ghasroldasht, M., Seok, J., Park, H. S., Liakath Ali, F. B. & Al-Hendy, A. Stem cell therapy: from idea to clinical practice. Int. J. Mol. Sci. 23, 2850 (2022).
Kuriyan, A. E. et al. Vision loss after intravitreal injection of autologous “stem cells” for AMD. N. Engl. J. Med. 376, 1047–1053 (2017).
Biehl, J. K. & Russell, B. Introduction to stem cell therapy. J. Cardiovasc. Nurs. 24, 98–103 (2009). quiz 104-105.
Srijaya, T. C., Ramasamy, T. S. & Kasim, N. H. Advancing stem cell therapy from bench to bedside: lessons from drug therapies. J. Transl. Med. 12, 243 (2014).
Ramalho-Santos, M. & Willenbring, H. On the origin of the term “stem cell”. Cell Stem Cell 1, 35–38 (2007).
Konstantinov, I. E. In search of Alexander A. Maximow: the man behind the unitarian theory of hematopoiesis. Perspect. Biol. Med. 43, 269–276 (2000).
Droscher, A. Images of cell trees, cell lines, and cell fates: the legacy of Ernst Haeckel and August Weismann in stem cell research. Hist. Philos. Life Sci. 36, 157–186 (2014).
Jansen, J. The first successful allogeneic bone-marrow transplant: Georges Mathe. Transfus. Med. Rev. 19, 246–248 (2005).
Blume, K. G. & Weissman, I. L. E. Donnall Thomas (1920-2012). Proc. Natl Acad. Sci. USA 109, 20777–20778 (2012).
Cheng, M. Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A. Clin. Transpl. 27, 326–329 (2013).
Thomas, E. D. et al. Aplastic anaemia treated by marrow transplantation. Lancet 1, 284–289 (1972).
Friedenstein, A. J., Chailakhyan, R. K. & Gerasimov, U. V. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet. 20, 263–272 (1987).
Friedenstein, A. J., Chailakhjan, R. K. & Lalykina, K. S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393–403 (1970).
Caplan, A. I. Mesenchymal stem cells. J. Orthop. Res. 9, 641–650 (1991).
Bolli, R., Tang, X. L., Guo, Y. & Li, Q. After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease. Can. J. Physiol. Pharm. 99, 129–139 (2021).
Liu, C., Han, D., Liang, P., Li, Y. & Cao, F. The current dilemma and breakthrough of stem cell therapy in ischemic heart disease. Front. Cell Dev. Biol. 9, 636136 (2021).
Zhang, J. et al. Basic and translational research in cardiac repair and regeneration: JACC state-of-the-art review. J. Am. Coll. Cardiol. 78, 2092–2105 (2021).
Gyongyosi, M., Wojakowski, W., Navarese, E. P., Moye, L. A. & Investigators, A. Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ. Res. 118, 1254–1263 (2016).
Okamoto, R., Matsumoto, T. & Watanabe, M. Regeneration of the intestinal epithelia: regulation of bone marrow-derived epithelial cell differentiation towards secretory lineage cells. Hum. Cell 19, 71–75 (2006).
Gehart, H. & Clevers, H. Tales from the crypt: new insights into intestinal stem cells. Nat. Rev. Gastroenterol. Hepatol. 16, 19–34 (2019).
Santos, A. J. M., Lo, Y. H., Mah, A. T. & Kuo, C. J. The intestinal stem cell niche: homeostasis and adaptations. Trends Cell Biol. 28, 1062–1078 (2018).
Roda, G. et al. Crohn’s disease. Nat. Rev. Dis. Prim. 6, 22 (2020).
Kobayashi, T. et al. Ulcerative colitis. Nat. Rev. Dis. Prim. 6, 74 (2020).
Gratwohl, A. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transpl. 35, 869–879 (2005).
Kashyap, A. & Forman, S. J. Autologous bone marrow transplantation for non-Hodgkin’s lymphoma resulting in long-term remission of coincidental Crohn’s disease. Br. J. Haematol. 103, 651–652 (1998).
Hurley, J. M., Lee, S. G., Andrews, R. E. Jr., Klowden, M. J. & Bulla, L. A. Jr. Separation of the cytolytic and mosquitocidal proteins of Bacillus thuringiensis subsp. israelensis. Biochem Biophys. Res. Commun. 126, 961–965 (1985).
Oyama, Y. et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology 128, 552–563 (2005).
Burt, R. K. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 116, 6123–6132 (2010).
Hasselblatt, P. et al. Remission of refractory Crohn’s disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharm. Ther. 36, 725–735 (2012).
Hawkey, C. J. et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. J. Am. Med. Assoc. 314, 2524–2534 (2015).
Lindsay, J. O. et al. Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol. Hepatol. 2, 399–406 (2017).
Wang, R. et al. Stem cell therapy for Crohn’s disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther. 12, 463 (2021).
Hawkey, C. J. Hematopoietic stem cell transplantation in Crohn’s disease: state-of-the-art treatment. Dig. Dis. 35, 107–114 (2017).
Si-Tayeb, K., Lemaigre, F. P. & Duncan, S. A. Organogenesis and development of the liver. Dev. Cell 18, 175–189 (2010).
Xue, R. et al. Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis. J. Transl. Med. 16, 126 (2018).
Shi, M. et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl. Med. 1, 725–731 (2012).
Liu, Y., Dong, Y., Wu, X., Xu, X. & Niu, J. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials. Stem Cell Res. Ther. 13, 204 (2022).
Lin, B. L. et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatology 66, 209–219 (2017).
Gordon, M. Y. et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 24, 1822–1830 (2006).
Arroyo, V. et al. Acute-on-chronic liver failure in cirrhosis. Nat. Rev. Dis. Prim. 2, 16041 (2016).
Zhang, Z. et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J. Gastroenterol. Hepatol. 27(Suppl 2), 112–120 (2012).
El-Ansary, M. et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev. Rep. 8, 972–981 (2012).
Xu, L. et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J. Gastroenterol. Hepatol. 29, 1620–1628 (2014).
Suk, K. T. et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology 64, 2185–2197 (2016).
Fang, X. et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. J. Gastroenterol. Hepatol. 33, 774–780 (2018).
Mohamadnejad, M. et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 33, 1490–1496 (2013).
Nguyen, T. L. et al. Autologous bone marrow mononuclear cell infusion for liver cirrhosis after the Kasai operation in children with biliary atresia. Stem Cell Res. Ther. 13, 108 (2022).
Bai, Y. Q. et al. Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis. World J. Gastroenterol. 20, 8660–8666 (2014).
Guo, C. et al. Long-term outcomes of autologous peripheral blood stem cell transplantation in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 17, 1175–1182 e1172 (2019).
Newsome, P. N. et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 25–36 (2018).
Spahr, L. et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS ONE 8, e53719 (2013).
Maurice, J. & Manousou, P. Non-alcoholic fatty liver disease. Clin. Med. 18, 245–250 (2018).
Huang, T. D., Behary, J. & Zekry, A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern. Med. J. 50, 1038–1047 (2020).
Sakai, Y. et al. Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regen. Ther. 18, 97–101 (2021).
Mieli-Vergani, G. et al. Autoimmune hepatitis. Nat. Rev. Dis. Primers 4, 18018 (2018).
Calore, E. et al. Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. Bone Marrow Transpl. 53, 644–646 (2018).
Vento, S., Cainelli, F., Renzini, C., Ghironzi, G. & Concia, E. Resolution of autoimmune hepatitis after bone-marrow transplantation. Lancet 348, 544–545 (1996).
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G. & Vergani, D. Autoimmmune hepatitis. Cell Mol. Immunol. 19, 158–176 (2022).
Wang, L. et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 28(Suppl 1), 85–92 (2013).
Wang, L. et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev. 23, 2482–2489 (2014).
Martel-Pelletier, J. et al. Osteoarthritis. Nat. Rev. Dis. Prim. 2, 16072 (2016).
Olsson, S., Akbarian, E., Lind, A., Razavian, A. S. & Gordon, M. Automating classification of osteoarthritis according to Kellgren-Lawrence in the knee using deep learning in an unfiltered adult population. BMC Musculoskelet. Disord. 22, 844 (2021).
Mahmoudian, A., Lohmander, L. S., Mobasheri, A., Englund, M. & Luyten, F. P. Early-stage symptomatic osteoarthritis of the knee—time for action. Nat. Rev. Rheumatol. 17, 621–632 (2021).
Kubsik-Gidlewska, A. et al. CD34+ stem cell treatment for knee osteoarthritis: a treatment and rehabilitation algorithm. J. Rehabil. Med Clin. Commun. 3, 1000012 (2018).
Jevotovsky, D. S., Alfonso, A. R., Einhorn, T. A. & Chiu, E. S. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthr. Cartil. 26, 711–729 (2018).
Wiggers, T. G., Winters, M., Van den Boom, N. A., Haisma, H. J. & Moen, M. H. Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials. Br. J. Sports Med 55, 1161–1169 (2021).
Han, S. B., Seo, I. W. & Shin, Y. S. Intra-articular injections of hyaluronic acid or steroids associated with better outcomes than platelet-rich plasma, adipose mesenchymal stromal cells, or placebo in knee osteoarthritis: a network meta-analysis. Arthroscopy 37, 292–306 (2021).
Bastos, R. et al. Intra-articular injections of expanded mesenchymal stem cells with and without addition of platelet-rich plasma are safe and effective for knee osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 26, 3342–3350 (2018).
Molnar, V. et al. Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. Genes 13, 949 (2022).
Barisic, S. & Childs, R. W. Graft-versus-solid-tumor effect: from hematopoietic stem cell transplantation to adoptive cell therapies. Stem Cells 40, 556–563 (2022).
Mello, M. M. & Brennan, T. A. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff. (Millwood) 20, 101–117 (2001).
Sissung, T. M. & Figg, W. D. Stem cell clinics: risk of proliferation. Lancet Oncol. 21, 205–206 (2020).
Fu, X. et al. Mesenchymal stem cell migration and tissue repair. Cells 8, 784 (2019).
Zachar, L., Bacenkova, D. & Rosocha, J. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment. J. Inflamm. Res. 9, 231–240 (2016).
de Araujo Farias, V., Carrillo-Galvez, A. B., Martin, F. & Anderson, P. TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 43, 25–37 (2018).
Ding, W. et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 116, 2984–2993 (2010).
Ritter, E. et al. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann. Surg. 247, 310–314 (2008).
Cronwright, G. et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 65, 2207–2215 (2005).
Aldinucci, D., Borghese, C. & Casagrande, N. The CCL5/CCR5 axis in cancer progression. Cancers 12, 1765 (2020).
Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557–563 (2007).
Kucerova, L., Matuskova, M., Hlubinova, K., Altanerova, V. & Altaner, C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 9, 129 (2010).
Schmohl, K. A., Muller, A. M., Nelson, P. J. & Spitzweg, C. Thyroid hormone effects on mesenchymal stem cell biology in the tumour microenvironment. Exp. Clin. Endocrinol. Diabetes 128, 462–468 (2020).
Mishra, P. J. et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68, 4331–4339 (2008).
Liu, J., Han, G., Liu, H. & Qin, C. Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling. PLoS ONE 8, e62844 (2013).
Ho, I. A. et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31, 146–155 (2013).
Sun, Z., Wang, S. & Zhao, R. C. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J. Hematol. Oncol. 7, 14 (2014).
Rhee, K. J., Lee, J. I. & Eom, Y. W. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int. J. Mol. Sci. 16, 30015–30033 (2015).
Liang, W. et al. Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell Mol. Biol. Lett. 26, 3 (2021).
Hmadcha, A., Martin-Montalvo, A., Gauthier, B. R., Soria, B. & Capilla-Gonzalez, V. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front. Bioeng. Biotechnol. 8, 43 (2020).
Cao, G. D. et al. The oncolytic virus in cancer diagnosis and treatment. Front. Oncol. 10, 1786 (2020).
Melen, G. J. et al. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 371, 161–170 (2016).
Garcia-Castro, J. et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 17, 476–483 (2010).
Draganov, D. D. et al. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. J. Transl. Med. 17, 100 (2019).
Cyranoski, D. How human embryonic stem cells sparked a revolution. Nature 555, 428–430 (2018).
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Gepstein, L. Derivation and potential applications of human embryonic stem cells. Circ. Res. 91, 866–876 (2002).
Andrews, P. W. From teratocarcinomas to embryonic stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 405–417 (2002).
Finch, B. W. & Ephrussi, B. Retention of multiple developmental potentialities by cells of a mouse testicular teratocarcinoma during prolonged culture in vitro and their extinction upon hybridization with cells of permanent lines. Proc. Natl Acad. Sci. USA 57, 615–621 (1967).
Ried, T. et al. The consequences of chromosomal aneuploidy on the transcriptome of cancer cells. Biochim Biophys. Acta 1819, 784–793 (2012).
Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156 (1981).
Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA 78, 7634–7638 (1981).
Lo, B. & Parham, L. Ethical issues in stem cell research. Endocr. Rev. 30, 204–213 (2009).
Wilmut, I., Schnieke, A. E., McWhir, J., Kind, A. J. & Campbell, K. H. Viable offspring derived from fetal and adult mammalian cells. Nature 385, 810–813 (1997).
Schwartz, S. D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713–720 (2012).
Atala, A. Human embryonic stem cells: early hints on safety and efficacy. Lancet 379, 689–690 (2012).
Schwartz, S. D. et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385, 509–516 (2015).
Song, W. K. et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 4, 860–872 (2015).
Liu, Y. et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov. 4, 50 (2018).
Limnios, I. J., Chau, Y. Q., Skabo, S. J., Surrao, D. C. & O’Neill, H. C. Efficient differentiation of human embryonic stem cells to retinal pigment epithelium under defined conditions. Stem Cell Res. Ther. 12, 248 (2021).
Foltz, L. P. & Clegg, D. O. Rapid, directed differentiation of retinal pigment epithelial cells from human embryonic or induced pluripotent stem cells. J. Vis. Exp. 128, e56274 (2017).
Kuroda, T., Ando, S., Takeno, Y., Kishino, A. & Kimura, T. Robust induction of retinal pigment epithelium cells from human induced pluripotent stem cells by inhibiting FGF/MAPK signaling. Stem Cell Res 39, 101514 (2019).
Dewell, T. E. et al. Transcription factor overexpression drives reliable differentiation of retinal pigment epithelium from human induced pluripotent stem cells. Stem Cell Res. 53, 102368 (2021).
Dehghan, S., Mirshahi, R., Shoae-Hassani, A. & Naseripour, M. Human-induced pluripotent stem cells-derived retinal pigmented epithelium, a new horizon for cells-based therapies for age-related macular degeneration. Stem Cell Res. Ther. 13, 217 (2022).
Menasche, P. et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36, 2011–2017 (2015).
Menasche, P. et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 71, 429–438 (2018).
Cyranoski, D. ‘Reprogrammed’ stem cells approved to mend human hearts for the first time. Nature 557, 619–620 (2018).
Povsic, T. J. & Gersh, B. J. Stem cells in cardiovascular diseases: 30,000-foot view. Cells 10, 600 (2021).
Romito, A. & Cobellis, G. Pluripotent stem cells: current understanding and future directions. Stem Cells Int. 2016, 9451492 (2016).
McKenna, S. L. et al. Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. J. Neurosurg. Spine 1, 1–10 (2022).
Deinsberger, J., Reisinger, D. & Weber, B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. NPJ Regen. Med. 5, 15 (2020).
Kim, J. Y., Nam, Y., Rim, Y. A. & Ju, J. H. Review of the current trends in clinical trials involving induced pluripotent stem cells. Stem Cell Rev. Rep. 18, 142–154 (2022).
Ji, P., Manupipatpong, S., Xie, N. & Li, Y. Induced pluripotent stem cells: generation strategy and epigenetic mystery behind reprogramming. Stem Cells Int. 2016, 8415010 (2016).
Fu, X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol. Immunol. 11, 14–16 (2014).
Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L. & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998–1004 (2013).
Friedenstein, A. J., Piatetzky, S. II & Petrakova, K. V. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16, 381–390 (1966).
Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
Nombela-Arrieta, C., Ritz, J. & Silberstein, L. E. The elusive nature and function of mesenchymal stem cells. Nat. Rev. Mol. Cell Biol. 12, 126–131 (2011).
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
Zhou, T. et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J. Hematol. Oncol. 14, 24 (2021).
Ankrum, J. & Karp, J. M. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 16, 203–209 (2010).
Tuan, R. S., Boland, G. & Tuli, R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res. Ther. 5, 32–45 (2003).
Witkowska-Zimny, M. & Wrobel, E. Perinatal sources of mesenchymal stem cells: Wharton’s jelly, amnion and chorion. Cell Mol. Biol. Lett. 16, 493–514 (2011).
Alkhalil, M., Smajilagic, A. & Redzic, A. Human dental pulp mesenchymal stem cells isolation and osteoblast differentiation. Med. Glas. (Zenica) 12, 27–32 (2015).
Ouryazdanpanah, N., Dabiri, S., Derakhshani, A., Vahidi, R. & Farsinejad, A. Peripheral blood-derived mesenchymal stem cells: growth factor-free isolation, molecular characterization and differentiation. Iran. J. Pathol. 13, 461–466 (2018).
Francis, M. P., Sachs, P. C., Elmore, L. W. & Holt, S. E. Isolating adipose-derived mesenchymal stem cells from lipoaspirate blood and saline fraction. Organogenesis 6, 11–14 (2010).
Gong, X. et al. Isolation and characterization of lung resident mesenchymal stem cells capable of differentiating into alveolar epithelial type II cells. Cell Biol. Int. 38, 405–411 (2014).
Wang, B. et al. Human hair follicle-derived mesenchymal stem cells: Isolation, expansion, and differentiation. World J. Stem Cells 12, 462–470 (2020).
Pilato, C. A. et al. Isolation and characterization of cardiac mesenchymal stromal cells from endomyocardial bioptic samples of arrhythmogenic cardiomyopathy patients. J. Vis. Exp. 132, e57263 (2018).
Mannino, G. et al. Adult stem cell niches for tissue homeostasis. J. Cell Physiol. 237, 239–257 (2022).
Pavlushina, S. V., Orlova, T. G. & Tabagari, D. Z. [Isolation of mononuclear cells from the bone marrow of patients with hemoblastoses using one-step ficoll-verographin density gradient separation]. Eksp. Onkol. 6, 68–70 (1984).
Schneider, S., Unger, M., van Griensven, M. & Balmayor, E. R. Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. Eur. J. Med Res. 22, 17 (2017).
Torre, P. & Flores, A. I. Current status and future prospects of perinatal stem cells. Genes 12, 6 (2020).
Hoang, V. T. et al. Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources. Cytotherapy 23, 88–99 (2020).
Mohamed-Ahmed, S. et al. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. Stem Cell Res. Ther. 9, 168 (2018).
Zuk, P. A. et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279–4295 (2002).
Li, Z. CD133: a stem cell biomarker and beyond. Exp. Hematol. Oncol. 2, 17 (2013).
Petrenko, Y. et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Sci. Rep. 10, 4290 (2020).
Wang, Z. & Yan, X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 330, 150–162 (2013).
Xu, L. et al. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res Ther. 8, 275 (2017).
Han, I., Kwon, B. S., Park, H. K. & Kim, K. S. Differentiation potential of mesenchymal stem cells is related to their intrinsic mechanical properties. Int. Neurourol. J. 21, S24–S31 (2017).
Song, Y. et al. Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms. World J. Stem Cells 12, 1032–1049 (2020).
Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63 (2009).
Allers, C. et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 78, 503–508 (2004).
Devine, S. M., Cobbs, C., Jennings, M., Bartholomew, A. & Hoffman, R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101, 2999–3001 (2003).
Fischer, U. M. et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 18, 683–692 (2009).
Sierra-Parraga, J. M. et al. Mesenchymal stromal cells are retained in the porcine renal cortex independently of their metabolic state after renal intra-arterial infusion. Stem Cells Dev. 28, 1224–1235 (2019).
Henriksson, H. B. et al. The traceability of mesenchymal stromal cells after injection into degenerated discs in patients with low back pain. Stem Cells Dev. 28, 1203–1211 (2019).
Sokal, E. M. et al. Biodistribution of liver-derived mesenchymal stem cells after peripheral injection in a hemophilia A patient. Transplantation 101, 1845–1851 (2017).
Sood, V. et al. Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery. Clin. Nucl. Med. 40, 697–700 (2015).
Sanchez-Diaz, M. et al. Biodistribution of mesenchymal stromal cells after administration in animal models and humans: a systematic review. J. Clin. Med. 10, 2925 (2021).
Sensebe, L. & Fleury-Cappellesso, S. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int. 2013, 678063 (2013).
Zhuang, W. Z. et al. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J. Biomed. Sci. 28, 28 (2021).
Wei, X. et al. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharm. Sin. 34, 747–754 (2013).
Kouchakian, M. R. et al. The clinical trials of mesenchymal stromal cells therapy. Stem Cells Int. 2021, 1634782 (2021).
Chen, L. et al. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol. Life Sci. 79, 142 (2022).
Borow, K. M., Yaroshinsky, A., Greenberg, B. & Perin, E. C. Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure. Circ. Res. 125, 265–281 (2019).
Zheng, H. et al. Mesenchymal stem cell therapy in stroke: a systematic review of literature in pre-clinical and clinical research. Cell Transpl. 27, 1723–1730 (2018).
Rodriguez-Fuentes, D. E. et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch. Med. Res. 52, 93–101 (2021).
Shi, L. et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct. Target Ther. 6, 339 (2021).
Carney, B. J. & Shah, K. Migration and fate of therapeutic stem cells in different brain disease models. Neuroscience 197, 37–47 (2011).
Yao, P., Zhou, L., Zhu, L., Zhou, B. & Yu, Q. Mesenchymal stem cells: a potential therapeutic strategy for neurodegenerative diseases. Eur. Neurol. 83, 235–241 (2020).
Bonaventura, G. et al. Stem cells: innovative therapeutic options for neurodegenerative diseases? Cells 10, 1992 (2021).
Mansoor, S. R., Zabihi, E. & Ghasemi-Kasman, M. The potential use of mesenchymal stem cells for the treatment of multiple sclerosis. Life Sci. 235, 116830 (2019).
Chung, J. W. et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. Neurology 96, e1012–e1023 (2021).
Yamazaki, K., Kawabori, M., Seki, T. & Houkin, K. Clinical trials of stem cell treatment for spinal cord injury. Int. J. Mol. Sci. 21, 3994 (2020).
Xie, B., Chen, M., Hu, R., Han, W. & Ding, S. Therapeutic evidence of human mesenchymal stem cell transplantation for cerebral palsy: a meta-analysis of randomized controlled trials. Stem Cells Int. 2020, 5701920 (2020).
McDonald, C. A. et al. Intranasal delivery of mesenchymal stromal cells protects against neonatal hypoxic(-)ischemic brain injury. Int. J. Mol. Sci. 20, 2449 (2019).
Liu, Q. et al. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World J. Stem Cells 11, 55–72 (2019).
Fricova, D., Korchak, J. A. & Zubair, A. C. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease. npj Regen. Med. 5, 20 (2020).
Bang, O. Y., Lee, J. S., Lee, P. H. & Lee, G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 57, 874–882 (2005).
Lee, J. S. et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28, 1099–1106 (2010).
Honmou, O. et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134, 1790–1807 (2011).
Bhasin, A. et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc. Dis. Extra 1, 93–104 (2011).
Jaillard, A. et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl. Stroke Res. 11, 910–923 (2020).
Lee, J. et al. Efficacy of intravenous mesenchymal stem cells for motor recovery after ischemic stroke: a neuroimaging study. Stroke 53, 20–28 (2022).
Levy, M. L. et al. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke 50, 2835–2841 (2019).
Xu, P. & Yang, X. The efficacy and safety of mesenchymal stem cell transplantation for spinal cord injury patients: a meta-analysis and systematic review. Cell Transpl. 28, 36–46 (2019).
Liau, L. L. et al. Treatment of spinal cord injury with mesenchymal stem cells. Cell Biosci. 10, 112 (2020).
Liu, X. et al. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J. Transl. Med. 15, 1–9 (2017).
Sharma, A. K. et al. Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study. Am J. Stem Cells 9, 89 (2020).
Ballen, K. & Kurtzberg, J. Exploring new therapies for children with autism: “Do no harm” does not mean do not try. Stem Cells Transl. Med. 10, 823–825 (2021).
Reyhani, S., Abbaspanah, B. & Mousavi, S. H. Umbilical cord-derived mesenchymal stem cells in neurodegenerative disorders: from literature to clinical practice. Regen. Med. 15, 1561–1578 (2020).
Gu, J. et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 11, 43 (2020).
Retraction. Stem Cells Transl. Med. 10, 1717 (2021).
Sun, J. M. et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl. Med. 9, 1137–1146 (2020).
Yang, Y. et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy 23, 57–64 (2021).
Liu, J. et al. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy 15, 185–191 (2013).
Przekora, A. & Juszkiewicz, L. The effect of autologous adipose tissue-derived mesenchymal stem cells’ therapy in the treatment of chronic posttraumatic spinal cord injury in a domestic ferret patient. Cell Transpl. 29, 963689720928982 (2020).
Hur, J. W. et al. Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial. J. Spinal Cord. Med. 39, 655–664 (2016).
de Celis-Ruiz, E. et al. Final results of allogeneic adipose tissue-derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. Cell Transpl. 31, 9636897221083863 (2022).
Yang, Y. et al. Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial. Neural Regen. Res. 15, 1532–1538 (2020).
de Celis-Ruiz, E. et al. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol. BMJ Open 11, e051790 (2021).
Murray, C. J. L. COVID-19 will continue but the end of the pandemic is near. Lancet 399, 417–419 (2022).
Thebaud, B. et al. Bronchopulmonary dysplasia. Nat. Rev. Dis. Prim. 5, 78 (2019).
Mohamed, T., Abdul-Hafez, A., Gewolb, I. H. & Uhal, B. D. Oxygen injury in neonates: which is worse? hyperoxia, hypoxia, or alternating hyperoxia/hypoxia. J. Lung Pulm. Respir. Res. 7, 4–13 (2020).
Omar, S. A. et al. Stem-cell therapy for bronchopulmonary dysplasia (BPD) in newborns. Cells 11, 1275 (2022).
Chang, Y. S. et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J. Pediatr. 164, 966–972 e966 (2014).
Powell, S. B. & Silvestri, J. M. Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants. J. Pediatr. 210, 209–213 e202 (2019).
Nguyen, L. T. et al. Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants. J. Transl. Med. 18, 398 (2020).
Ahn, S. Y. et al. Stem cells for bronchopulmonary dysplasia in preterm infants: a randomized controlled phase II trial. Stem Cells Transl. Med. 10, 1129–1137 (2021).
Averyanov, A. et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl. Med. 9, 6–16 (2020).
Ribeiro-Paes, J. T. et al. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int. J. Chron. Obstruct Pulmon Dis. 6, 63–71 (2011).
Stessuk, T. et al. Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years. Rev. Bras. Hematol. Hemoter. 35, 352–357 (2013).
Weiss, D. J., Casaburi, R., Flannery, R., LeRoux-Williams, M. & Tashkin, D. P. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143, 1590–1598 (2013).
de Oliveira, H. G. et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: a phase I clinical trial. Stem Cells Transl. Med. 6, 962–969 (2017).
Stolk, J. et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM 109, 331–336 (2016).
de Oliveira, H. G. et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: a phase I clinical trial. Stem Cells Transl. Med. 6, 962–969 (2017).
Armitage, J. et al. Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study. Eur. Respir. J. 51, 1702369 (2018).
Comella, K. et al. Autologous stromal vascular fraction in the intravenous treatment of end-stage chronic obstructive pulmonary disease: a phase I trial of safety and tolerability. J. Clin. Med. Res. 9, 701–708 (2017).
Tzilas, V. et al. Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE). Eur. Respir. J. 46, (2015).
Comella, K. et al. Autologous stromal vascular fraction in the intravenous treatment of end-stage chronic obstructive pulmonary disease: a phase I trial of safety and tolerability. J. Clin. Med. Res. 9, 701–708 (2017).
Glassberg, M. K., Csete, I., Simonet, E. & Elliot, S. J. Stem cell therapy for COPD: hope and exploitation. Chest 160, 1271–1281 (2021).
Le Thi Bich, P. et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study. Stem Cell Res. Ther. 60, 11 (2020).
Karaoz, E., Kalemci, S. & Ece, F. Improving effects of mesenchymal stem cells on symptoms of chronic obstructive pulmonary disease. Bratisl. Lek. Listy. 121, 188–191 (2020).
Hoang, D. M., Nguyen, K. T., Nguyen, A. H., Nguyen, B. N. & Nguyen, L. T. Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case-control, phase I/II trial. BMJ Open 11, e045788 (2021).
Xu, R., Feng, Z. & Wang, F. S. Mesenchymal stem cell treatment for COVID-19. EBioMedicine 77, 103920 (2022).
Khoury, M. et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur. Respir. J. 55, 2000858 (2020).
Jamilloux, Y. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 19, 102567 (2020).
Feng, Y. et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: a pilot study. Cell Prolif. 53, e12947 (2020).
Primorac, D. et al. Mesenchymal stromal cells: potential option for COVID-19 treatment. Pharmaceutic 13, 1481 (2021).
Zhang, Y. et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res. Ther. 11, 207 (2020).
Shu, L. et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 11, 361 (2020).
Tao, J. et al. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient. J. Infect. Dev. Ctries 14, 1138–1145 (2020).
Saleh, M. et al. Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res. Ther. 12, 410 (2021).
Leng, Z. et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 11, 216–228 (2020).
Guo, Z. et al. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit. Care 24, 420 (2020).
Meng, F. et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct. Target Ther. 5, 172 (2020).
Shi, L. et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 75, 103789 (2021).
Adas, G. et al. The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transpl. 30, 9636897211024942 (2021).
Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Targeted Ther. 6, 58 (2021).
Lanzoni, G. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 10, 660–673 (2021).
Hashemian, S. R. et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 12, 91 (2021).
Zhu, R. et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 31, 1244–1262 (2021).
Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target Ther. 6, 58 (2021).
N, O. E., Pekkoc-Uyanik, K. C., Alpaydin, N., Gulay, G. R. & Simsek, M. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. Stem Cell Rev. Rep. 17, 1917–1925 (2021).
Gentile, P., Sterodimas, A., Pizzicannella, J., Calabrese, C. & Garcovich, S. Research progress on mesenchymal stem cells (MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), drugs, and vaccines in inhibiting COVID-19 disease. Aging Dis. 11, 1191–1201 (2020).
Copcu, H. E. Potential using of fat-derived stromal cells in the treatment of active disease, and also, in both pre- and post-periods in COVID-19. Aging Dis. 11, 730–736 (2020).
Gentile, P. & Sterodimas, A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin. Biol. Ther. 20, 711–716 (2020).
Matthay, M. A. et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir. Med. 7, 154–162 (2019).
Álvarez-Fuente, M. et al. Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile. Cytotherapy 20, 1337–1344 (2018).
Zheng, G. et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir. Res. 15, 39 (2014).
Simonson, O. E. et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl. Med. 4, 1199–1213 (2015).
Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24–32 (2015).
Matthay, M. A. et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir. Med. 7, 154–162 (2019).
Yip, H. K. et al. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit. Care Med 48, e391–e399 (2020).
Gorman, E. et al. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: a phase 1 trial. EClinicalMedicine 41, 101167 (2021).
Le Thi Bich, P. et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study. Stem Cell Res. Ther. 11, 60 (2020).
Wang, M. Y. et al. Current therapeutic strategies for respiratory diseases using mesenchymal stem cells. MedComm 2, 351–380 (2021).
Carlsson, P. O., Schwarcz, E., Korsgren, O. & Le Blanc, K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 64, 587–592 (2015).
Dantas, J. R. et al. Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients. Arch. Endocrinol. Metab. 65, 342–351 (2021).
Joseph, U. A. & Jhingran, S. G. Technetium-99m labeled RBC imaging in gastrointestinal bleeding from gastric leiomyoma. Clin. Nucl. Med. 13, 23–25 (1988).
Hu, J. et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr. J. 60, 347–357 (2013).
Cai, J. et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care 39, 149–157 (2016).
Huang, Q., Huang, Y. & Liu, J. Mesenchymal stem cells: an excellent candidate for the treatment of diabetes mellitus. Int. J. Endocrinol. 2021, 9938658 (2021).
Nguyen, L. T. et al. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl. Med. 10, 1266–1278 (2021).
Alicka, M., Major, P., Wysocki, M. & Marycz, K. Adipose-derived mesenchymal stem cells isolated from patients with type 2 diabetes show reduced “stemness” through an altered secretome profile, impaired anti-oxidative protection, and mitochondrial dynamics deterioration. J. Clin. Med. 8, 765 (2019).
Agarwal, A. et al. Male infertility. Lancet 397, 319–333 (2021).
Farquhar, C. & Marjoribanks, J. Assisted reproductive technology: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 8, CD010537 (2018).
Chang, Z. et al. Mesenchymal stem cells in preclinical infertility cytotherapy: a retrospective review. Stem Cells Int. 2021, 8882368 (2021).
Fenton, A. J. Premature ovarian insufficiency: pathogenesis and management. J. Midlife Health 6, 147–153 (2015).
Coulam, C. B. Premature gonadal failure. Fertil. Steril. 38, 645–655 (1982).
Huhtaniemi, I. et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol. Metab. 29, 400–419 (2018).
Torrealday, S., Kodaman, P. & Pal, L. Premature ovarian Insufficiency—an update on recent advances in understanding and management. F1000Res 6, 2069 (2017).
Gupta, S., Lodha, P., Karthick, M. S. & Tandulwadkar, S. R. Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: review of literature and a case report of world’s first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year. J. Hum. Reprod. Sci. 11, 125–130 (2018).
Igboeli, P. et al. Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: two case reports and a review of the literature. J. Med. Case Rep. 14, 108 (2020).
Ulin, M. et al. Human mesenchymal stem cell therapy and other novel treatment approaches for premature ovarian insufficiency. Reprod. Sci. 28, 1688–1696 (2021).
Herraiz, S. et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil. Steril. 110, 496–505 e491 (2018).
Ding, L. et al. Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility. Sci. China Life Sci. 61, 1554–1565 (2018).
Wang, M. Y., Wang, Y. X., Li-Ling, J. & Xie, H. Q. Adult stem cell therapy for premature ovarian failure: from bench to bedside. Tissue Eng. Part B Rev. 28, 63–78 (2022).
Kaddoura, I., Abu-Sittah, G., Ibrahim, A., Karamanoukian, R. & Papazian, N. Burn injury: review of pathophysiology and therapeutic modalities in major burns. Ann. Burns Fire Disasters 30, 95–102 (2017).
Jeschke, M. G. et al. Burn injury. Nat. Rev. Dis. Prim. 6, 11 (2020).
Rasulov, M. F. et al. First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Bull. Exp. Biol. Med. 139, 141–144 (2005).
Mansilla, E. et al. Cadaveric bone marrow mesenchymal stem cells: first experience treating a patient with large severe burns. Burns Trauma 3, 17 (2015).
Xu, Y., Huang, S. & Fu, X. Autologous transplantation of bone marrow-derived mesenchymal stem cells: a promising therapeutic strategy for prevention of skin-graft contraction. Clin. Exp. Dermatol. 37, 497–500 (2012).
Yoshikawa, T. et al. Wound therapy by marrow mesenchymal cell transplantation. Plast. Reconstr. Surg. 121, 860–877 (2008).
Abo-Elkheir, W. et al. Role of cord blood and bone marrow mesenchymal stem cells in recent deep burn: a case-control prospective study. Am. J. Stem Cells 6, 23–35 (2017).
Li, L. et al. Conditioned medium from human adipose-derived mesenchymal stem cell culture prevents UVB-induced skin aging in human keratinocytes and dermal fibroblasts. Int. J. Mol. Sci. 21, 49 (2019).
Lotfi, M. et al. Adipose tissue-derived mesenchymal stem cells and keratinocytes co-culture on gelatin/chitosan/beta-glycerol phosphate nanoscaffold in skin regeneration. Cell Biol. Int. 43, 1365–1378 (2019).
Yang, J. A., Chung, H. M., Won, C. H. & Sung, J. H. Potential application of adipose-derived stem cells and their secretory factors to skin: discussion from both clinical and industrial viewpoints. Expert Opin. Biol. Ther. 10, 495–503 (2010).
Zhou, Y. et al. Combined topical and systemic administration with human adipose-derived mesenchymal stem cells (hADSC) and hADSC-derived exosomes markedly promoted cutaneous wound healing and regeneration. Stem Cell Res. Ther. 12, 257 (2021).
Arjmand, B. et al. Regenerative medicine for the treatment of ischemic heart disease; status and future perspectives. Front. Cell Dev. Biol. 9, 704903 (2021).
Denning, C. et al. Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. Biochim Biophys. Acta 1863, 1728–1748 (2016).
Wu, R., Hu, X. & Wang, J. Concise review: optimized strategies for stem cell-based therapy in myocardial repair: clinical translatability and potential limitation. Stem Cells 36, 482–500 (2018).
Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).
Bagno, L., Hatzistergos, K. E., Balkan, W. & Hare, J. M. Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges. Mol. Ther. 26, 1610–1623 (2018).
Demurtas, J. et al. Stem cells for treatment of cardiovascular diseases: an umbrella review of randomized controlled trials. Ageing Res. Rev. 67, 101257 (2021).
Gubert, F. et al. Mesenchymal stem cells therapies on fibrotic heart diseases. Int. J. Mol. Sci. 22, 7447 (2021).
da Silva, J. S. et al. Mesenchymal stem cell therapy in diabetic cardiomyopathy. Cells 11, 240 (2022).
He, X. et al. Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduct. Target Ther. 7, 134 (2022).
Bolli, R., Solankhi, M., Tang, X. L. & Kahlon, A. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 118, 951–976 (2022).
Bartunek, J. et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61, 2329–2338 (2013).
Bartunek, J. et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur. Heart J. 38, 648–660 (2017).
Hare, J. M. et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. J. Am. Med. Assoc. 308, 2369–2379 (2012).
Hare, J. M. et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J. Am. Coll. Cardiol. 69, 526–537 (2017).
Mathiasen, A. B. et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur. Heart J. 36, 1744–1753 (2015).
Mathiasen, A. B. et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial. Eur. J. Heart Fail 22, 884–892 (2020).
Florea, V. et al. Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study). Circ. Res. 121, 1279–1290 (2017).
Bolli, R. et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur. J. Heart Fail 23, 661–674 (2021).
Heldman, A. W. et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. J. Am. Med. Assoc. 311, 62–73 (2014).
Perin, E. C. et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE trial. Am. Heart J. 168, 88–95 e82 (2014).
Han, S., Sun, H. M., Hwang, K. C. & Kim, S. W. Adipose-derived stromal vascular fraction cells: update on clinical utility and efficacy. Crit. Rev. Eukaryot. Gene Expr. 25, 145–152 (2015).
Henry, T. D. et al. The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Inter. 89, 169–177 (2017).
Kastrup, J. et al. Cryopreserved off-the-shelf allogeneic adipose-derived stromal cells for therapy in patients with ischemic heart disease and heart failure—a safety study. Stem Cells Transl. Med. 6, 1963–1971 (2017).
Qayyum, A. A. et al. Adipose-derived stromal cells for treatment of patients with chronic ischemic heart disease (MyStromalCell Trial): a randomized placebo-controlled study. Stem Cells Int. 2017, 5237063 (2017).
Qayyum, A. A. et al. Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. J. Transl. Med. 17, 360 (2019).
Ngo, A. T. L. et al. Clinically relevant preservation conditions for mesenchymal stem/stromal cells derived from perinatal and adult tissue sources. J. Cell Mol. Med. 25, 10747–10760 (2021).
Madonna, R., Cevik, C., Nasser, M. & De Caterina, R. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. Thromb. Haemost. 107, 656–661 (2012).
Bartolucci, J. et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD Trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ. Res. 121, 1192–1204 (2017).
Ulus, A. T. et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART trial). Int. J. Stem Cells 13, 364–376 (2020).
He, X. et al. Effect of intramyocardial grafting collagen scaffold with mesenchymal stromal cells in patients with chronic ischemic heart disease: a randomized clinical trial. JAMA Netw. Open 3, e2016236 (2020).
Zhang, Q. et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct. Target Ther. 7, 78 (2022).
Poomani, M. S. et al. Mesenchymal stem cell (MSCs) therapy for ischemic heart disease: a promising frontier. Glob. Heart 17, 19 (2022).
Xu, W. et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med. 229, 623–631 (2004).
Jeong, J. O. et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ. Res. 108, 1340–1347 (2011).
Denu, R. A. et al. Fibroblasts and mesenchymal stromal/stem cells are phenotypically indistinguishable. Acta Haematol. 136, 85–97 (2016).
Birbrair, A. & Frenette, P. S. Niche heterogeneity in the bone marrow. Ann. N. Y Acad. Sci. 1370, 82–96 (2016).
Pinho, S. & Frenette, P. S. Haematopoietic stem cell activity and interactions with the niche. Nat. Rev. Mol. Cell Biol. 20, 303–320 (2019).
Ono, N. et al. Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. Dev. Cell 29, 330–339 (2014).
Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977–988 (2006).
Ehninger, A. & Trumpp, A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J. Exp. Med. 208, 421–428 (2011).
Golan, K., Kollet, O., Markus, R. P. & Lapidot, T. Daily light and darkness onset and circadian rhythms metabolically synchronize hematopoietic stem cell differentiation and maintenance: the role of bone marrow norepinephrine, tumor necrosis factor, and melatonin cycles. Exp. Hematol. 78, 1–10 (2019).
Cheng, X. et al. The role of SDF-1/CXCR4/CXCR7 in neuronal regeneration after cerebral ischemia. Front. Neurosci. 11, 590 (2017).
Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595–599 (1998).
Mao, W., Yi, X., Qin, J., Tian, M. & Jin, G. CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury. Int. J. Neurosci. 124, 281–290 (2014).
Wang, Q. et al. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer’s disease mouse model. Brain Res. 1459, 15–26 (2012).
Yellowley, C. CXCL12/CXCR4 signaling and other recruitment and homing pathways in fracture repair. Bonekey Rep. 2, 300 (2013).
Li, J. et al. CXCL12 promotes spinal nerve regeneration and functional recovery after spinal cord injury. Neuroreport 32, 450–457 (2021).
Gensel, J. C., Kigerl, K. A., Mandrekar-Colucci, S. S., Gaudet, A. D. & Popovich, P. G. Achieving CNS axon regeneration by manipulating convergent neuro-immune signaling. Cell Tissue Res. 349, 201–213 (2012).
Matsushita, T. et al. Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neurosci. Lett. 502, 41–45 (2011).
Schmidt, A. et al. Mesenchymal stem cells transmigrate over the endothelial barrier. Eur. J. Cell Biol. 85, 1179–1188 (2006).
Yarygin, K. N. et al. Cell therapy of stroke: do the intra-arterially transplanted mesenchymal stem cells cross the blood-brain barrier? Cells 10, 2997 (2021).
Schack, L. M. et al. Expression of CD24 in human bone marrow-derived mesenchymal stromal cells is regulated by TGFbeta3 and induces a myofibroblast-like genotype. Stem Cells Int. 2016, 1319578 (2016).
Ruster, B. et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108, 3938–3944 (2006).
Pluchino, N. et al. CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking. J. Cell Mol. Med. 24, 2464–2474 (2020).
Kowalski, K. et al. Stem cells migration during skeletal muscle regeneration—the role of Sdf-1/Cxcr4 and Sdf-1/Cxcr7 axis. Cell Adh. Migr. 11, 384–398 (2017).
Liu, L. et al. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? Stem Cells Int. 2013, 435093 (2013).
Lozito, T. P. & Tuan, R. S. Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. J. Cell Physiol. 226, 385–396 (2011).
Lozito, T. P., Jackson, W. M., Nesti, L. J. & Tuan, R. S. Human mesenchymal stem cells generate a distinct pericellular zone of MMP activities via binding of MMPs and secretion of high levels of TIMPs. Matrix Biol. 34, 132–143 (2014).
Menge, T. et al. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci. Transl. Med. 4, 161ra150 (2012).
Franklin, R. J. M. & Ffrench-Constant, C. Regenerating CNS myelin—from mechanisms to experimental medicines. Nat. Rev. Neurosci. 18, 753–769 (2017).
Brick, R. M., Sun, A. X. & Tuan, R. S. Neurotrophically induced mesenchymal progenitor cells derived from induced pluripotent stem cells enhance neuritogenesis via neurotrophin and cytokine production. Stem Cells Transl. Med. 7, 45–58 (2018).
Zupanc, H. R. H., Alexander, P. G. & Tuan, R. S. Neurotrophic support by traumatized muscle-derived multipotent progenitor cells: role of endothelial cells and vascular endothelial growth factor-A. Stem Cell Res. Ther. 8, 226 (2017).
Liu, Y. & Olsen, B. R. Distinct VEGF functions during bone development and homeostasis. Arch. Immunol. Ther. Exp. 62, 363–368 (2014).
Kangari, P., Talaei-Khozani, T., Razeghian-Jahromi, I. & Razmkhah, M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. Stem Cell Res. Ther. 11, 492 (2020).
Liu, Y. et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J. Clin. Investig. 122, 3101–3113 (2012).
Berendsen, A. D. & Olsen, B. R. How vascular endothelial growth factor-A (VEGF) regulates differentiation of mesenchymal stem cells. J. Histochem Cytochem. 62, 103–108 (2014).
Garcia, K. O. et al. Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer’s disease. Front. Aging Neurosci. 6, 30 (2014).
Hohman, T. J., Bell, S. P. & Jefferson, A. L., Alzheimer’s Disease Neuroimaging, I. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol. 72, 520–529 (2015).
Zhang, W. et al. Neuroprotective effects of SOX5 against ischemic stroke by regulating VEGF/PI3K/AKT pathway. Gene 767, 145148 (2021).
Jin, K. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl Acad. Sci. USA 99, 11946–11950 (2002).
Bao, X. J. et al. Transplantation of Flk-1+ human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and anti-inflammatory and angiogenesis effects in an intracerebral hemorrhage rat model. Int. J. Mol. Med. 31, 1087–1096 (2013).
Bao, X. et al. Transplantation of Flk-1+ human bone marrow-derived mesenchymal stem cells promotes angiogenesis and neurogenesis after cerebral ischemia in rats. Eur. J. Neurosci. 34, 87–98 (2011).
Pelletier, J. et al. VEGF-A promotes both pro-angiogenic and neurotrophic capacities for nerve recovery after compressive neuropathy in rats. Mol. Neurobiol. 51, 240–251 (2015).
Hobson, M. I., Green, C. J. & Terenghi, G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J. Anat. 197(Pt 4), 591–605 (2000).
Hayakawa, K. et al. Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. J. Neurosci. 31, 10666–10670 (2011).
Pei, G., Xu, L., Huang, W. & Yin, J. The protective role of microRNA-133b in restricting hippocampal neurons apoptosis and inflammatory injury in rats with depression by suppressing CTGF. Int. Immunopharmacol. 78, 106076 (2020).
Xu, H. et al. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/beta-catenin signaling pathway by targeting EZH2. Stem Cell Res. Ther. 10, 381 (2019).
Xin, H. et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells 31, 2737–2746 (2013).
Kigerl, K. A. et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J. Neurosci. 29, 13435–13444 (2009).
Knoller, N. et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J. Neurosurg. Spine 3, 173–181 (2005).
Yagura, K. et al. The enhancement of CCL2 and CCL5 by human bone marrow-derived mesenchymal stem/stromal cells might contribute to inflammatory suppression and axonal extension after spinal cord injury. PLoS ONE 15, e0230080 (2020).
Zhong, Z. et al. Bone marrow mesenchymal stem cells upregulate PI3K/AKT pathway and down-regulate NF-kappaB pathway by secreting glial cell-derived neurotrophic factors to regulate microglial polarization and alleviate deafferentation pain in rats. Neurobiol. Dis. 143, 104945 (2020).
Zhong, Z. et al. Adipose-derived stem cells modulate BV2 microglial M1/M2 polarization by producing GDNF. Stem Cells Dev. 29, 714–727 (2020).
Dong, B. et al. Exosomes from human umbilical cord mesenchymal stem cells attenuate the inflammation of severe steroid-resistant asthma by reshaping macrophage polarization. Stem Cell Res. Ther. 12, 204 (2021).
Li, X. et al. Umbilical cord tissue-derived mesenchymal stem cells induce T lymphocyte apoptosis and cell cycle arrest by expression of indoleamine 2, 3-dioxygenase. Stem Cells Int. 2016, 7495135 (2016).
Wang, A. Y. L. et al. Human Wharton’s jelly mesenchymal stem cell-mediated sciatic nerve recovery is associated with the upregulation of regulatory T cells. Int. J. Mol. Sci. 21, 6310 (2020).
Noone, C., Kihm, A., English, K., O’Dea, S. & Mahon, B. P. IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 22, 3003–3014 (2013).
Li, X. et al. Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury. Stem Cell Res. Ther. 13, 18 (2022).
Shang, Y., Guan, H. & Zhou, F. Biological characteristics of umbilical cord mesenchymal stem cells and its therapeutic potential for hematological disorders. Front. Cell Dev. Biol. 9, 570179 (2021).
Mennan, C. et al. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed. Res. Int. 2013, 916136 (2013).
D’Addio, F. et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 187, 4530–4541 (2011).
Amable, P. R., Teixeira, M. V., Carias, R. B., Granjeiro, J. M. & Borojevic, R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Res. Ther. 5, 53 (2014).
de Witte, S. F. H. et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells 36, 602–615 (2018).
Li, Y. et al. Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. Cell Mol. Immunol. 16, 908–920 (2019).
De Paepe, M. E., Wong, T., Chu, S. & Mao, Q. Stromal cell-derived factor-1 (SDF-1) expression in very preterm human lungs: potential relevance for stem cell therapy for bronchopulmonary dysplasia. Exp. Lung Res. 46, 146–156 (2020).
Wynn, R. F. et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104, 2643–2645 (2004).
Ryu, C. H. et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys. Res. Commun. 398, 105–110 (2010).
Yang, C. et al. The biological changes of umbilical cord mesenchymal stem cells in inflammatory environment induced by different cytokines. Mol. Cell Biochem. 446, 171–184 (2018).
Seedorf, G. et al. Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L1098–L1110 (2016).
Chen, X. Y. et al. Therapeutic potential of human umbilical cord-derived mesenchymal stem cells in recovering from murine pulmonary emphysema under cigarette smoke exposure. Front. Med. 8, 713824 (2021).
Katsha, A. M. et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol. Ther. 19, 196–203 (2011).
Kyurkchiev, D. et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J. Stem Cells 6, 552–570 (2014).
Ren, Z. et al. Human umbilical-cord mesenchymal stem cells inhibit bacterial growth and alleviate antibiotic resistance in neonatal imipenem-resistant Pseudomonas aeruginosa infection. Innate Immun. 26, 215–221 (2020).
Liu, J. et al. Type 2 alveolar epithelial cells differentiated from human umbilical cord mesenchymal stem cells alleviate mouse pulmonary fibrosis through beta-catenin-regulated cell apoptosis. Stem Cells Dev. 30, 660–670 (2021).
Moodley, Y. et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am. J. Pathol. 175, 303–313 (2009).
Li, D. Y., Li, R. F., Sun, D. X., Pu, D. D. & Zhang, Y. H. Mesenchymal stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies. Stem Cell Res. Ther. 12, 461 (2021).
Lam, G., Zhou, Y., Wang, J. X. & Tsui, Y. P. Targeting mesenchymal stem cell therapy for severe pneumonia patients. World J. Stem Cells 13, 139–154 (2021).
Chen, K. et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin. Immunol. 135, 448–458 (2010).
Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141–150 (2008).
Loy, H. et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virus-associated acute lung injury. J. Infect. Dis. 219, 186–196 (2019).
Gazdhar, A. et al. Targeted gene transfer of hepatocyte growth factor to alveolar type II epithelial cells reduces lung fibrosis in rats. Hum. Gene Ther. 24, 105–116 (2013).
Wang, W. et al. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. J. Transl. Med. 19, 198 (2021).
Chu, K. A. et al. Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly. Theranostics 9, 6646–6664 (2019).
Chen, Q. H. et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro. Stem Cell Res. Ther. 11, 91 (2020).
Li, L. et al. Human umbilical cord-derived mesenchymal stem cells downregulate inflammatory responses by shifting the Treg/Th17 profile in experimental colitis. Pharmacology 92, 257–264 (2013).
Zheng, L., Wang, S., Yang, H. & Lyu, X. [Research progress of mesenchymal stem cells attenuating acute respiratory distress syndrome by regulating the balance of M1/M2 macrophage polarization]. Zhonghua Wei Zhong Bing. Ji Jiu Yi Xue 33, 509–512 (2021).
Fasshauer, M. & Bluher, M. Adipokines in health and disease. Trends Pharm. Sci. 36, 461–470 (2015).
Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004).
Kurylowicz, A. & Kozniewski, K. Anti-inflammatory strategies targeting metaflammation in type 2 diabetes. Molecules 25, 2224 (2020).
Liu, J. et al. Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats. Mol. Cells 37, 865–872 (2014).
Jalalie, L. et al. Distribution of the CM-Dil-labeled human umbilical cord vein mesenchymal stem cells migrated to the cyclophosphamide-injured ovaries in C57BL/6 mice. Iran. Biomed. J. 23, 200–208 (2019).
Takehara, Y. et al. The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function. Lab. Investig. 93, 181–193 (2013).
Richards, J. S., Ren, Y. A., Candelaria, N., Adams, J. E. & Rajkovic, A. Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update. Endocr. Rev. 39, 1–20 (2018).
Young, J. M. & McNeilly, A. S. Theca: the forgotten cell of the ovarian follicle. Reproduction 140, 489–504 (2010).
Trzyna, A. & Banas-Zabczyk, A. Adipose-derived stem cells secretome and its potential application in “stem cell-free therapy”. Biomolecules 11, 878 (2021).
Ding, C. et al. Human amniotic mesenchymal stem cells improve ovarian function in natural aging through secreting hepatocyte growth factor and epidermal growth factor. Stem Cell Res. Ther. 9, 55 (2018).
Kedenko, L. et al. Genetic polymorphisms at SIRT1 and FOXO1 are associated with carotid atherosclerosis in the SAPHIR cohort. BMC Med. Genet. 15, 112 (2014).
Shojafar, E., Soleimani Mehranjani, M. & Shariatzadeh, S. M. A. Adipose derived mesenchymal stem cells improve the structure and function of autografted mice ovaries through reducing oxidative stress and inflammation: a stereological and biochemical analysis. Tissue Cell 56, 23–30 (2019).
Liu, M. et al. Small extracellular vesicles derived from embryonic stem cells restore ovarian function of premature ovarian failure through PI3K/AKT signaling pathway. Stem Cell Res. Ther. 11, 3 (2020).
Li, Z., Zhang, M., Tian, Y., Li, Q. & Huang, X. Mesenchymal stem cells in premature ovarian insufficiency: mechanisms and prospects. Front. Cell Dev. Biol. 9, 718192 (2021).
Forghani, A. et al. Differentiation of adipose tissue-derived CD34+/CD31- cells into endothelial cells in vitro. Regen. Eng. Transl. Med 6, 101–110 (2020).
Baer, P. C. Adipose-derived stem cells and their potential to differentiate into the epithelial lineage. Stem Cells Dev. 20, 1805–1816 (2011).
Wang, C. et al. Differentiation of adipose-derived stem cells into contractile smooth muscle cells induced by transforming growth factor-beta1 and bone morphogenetic protein-4. Tissue Eng. Part A 16, 1201–1213 (2010).
Chen, L. et al. Adipose-derived stem cells promote diabetic wound healing via the recruitment and differentiation of endothelial progenitor cells into endothelial cells mediated by the VEGF-PLCgamma-ERK pathway. Arch. Biochem Biophys. 692, 108531 (2020).
Dekoninck, S. & Blanpain, C. Stem cell dynamics, migration and plasticity during wound healing. Nat. Cell Biol. 21, 18–24 (2019).
Qian, L., Pi, L., Fang, B. R. & Meng, X. X. Adipose mesenchymal stem cell-derived exosomes accelerate skin wound healing via the lncRNA H19/miR-19b/SOX9 axis. Lab. Investig. 101, 1254–1266 (2021).
Fujiwara, O. et al. Adipose-derived stem cells improve grafted burn wound healing by promoting wound bed blood flow. Burns Trauma 8, tkaa009 (2020).
Chen, T. et al. Efficient and sustained IGF-1 expression in the adipose tissue-derived stem cells mediated via a lentiviral vector. J. Mol. Histol. 46, 1–11 (2015).
Zhou, K. et al. Immunosuppression of human adipose-derived stem cells on T cell subsets via the reduction of NF-kappaB activation mediated by PD-L1/PD-1 and Gal-9/TIM-3 pathways. Stem Cells Dev. 27, 1191–1202 (2018).
Moll, G. et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol. Med. 25, 149–163 (2019).
He, X. et al. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduct. Target Ther. 6, 270 (2021).
Lukomska, B. et al. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019, 9628536 (2019).
Li, C., Zhao, H. & Wang, B. Challenges for mesenchymal stem cell-based therapy for COVID-19. Drug Des. Devel Ther. 14, 3995–4001 (2020).
Nguyen Thanh, L. et al. Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder. Stem Cells Transl. Med. 10, 14–26 (2020).
Nguyen Thanh, L. et al. Can autologous adipose-derived mesenchymal stem cell transplantation improve sexual function in people with sexual functional deficiency? Stem Cell Rev. Rep. 17, 2153–2163 (2021).
Caplan, A. I. Mesenchymal stem cells: time to change the name! Stem Cells Transl. Med. 6, 1445–1451 (2017).
de Windt, T. S., Vonk, L. A. & Saris, D. B. F. Response to: Mesenchymal stem cells: time to change the name! Stem Cells Transl. Med. 6, 1747–1748 (2017).
Boregowda, S. V., Booker, C. N. & Phinney, D. G. Mesenchymal stem cells: the moniker fits the science. Stem Cells 36, 7–10 (2018).
Masterson, C. & O’Toole, D. The mesenchymal stromal cell magic bullet finds yet another target. Stem Cell Res. Ther. 5, 82 (2014).
Murray, I. R. et al. Rogue stem cell clinics. Bone Jt. J. 102-B, 148–154 (2020).
Lyons, S., Salgaonkar, S. & Flaherty, G. T. International stem cell tourism: a critical literature review and evidence-based recommendations. Int. Health 14, 132–141 (2022).
He, C. et al. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges. Ther. Adv. Chronic Dis. 12, 2040622321993442 (2021).
Bertheuil, N. et al. Adipose mesenchymal stromal cells: definition, immunomodulatory properties, mechanical isolation and interest for plastic surgery. Ann. Chir. Plast. Esthet. 64, 1–10 (2019).
Chen, Y., Yu, Q., Hu, Y. & Shi, Y. Current research and use of mesenchymal stem cells in the therapy of autoimmune diseases. Curr. Stem Cell Res. Ther. 14, 579–582 (2019).
Han, Y. et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct. Target Ther. 7, 92 (2022).
Rahmani, A. et al. Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke. Ageing Res. Rev. 62, 101106 (2020).
Zhou, W. et al. Single-cell profiles and clinically useful properties of human mesenchymal stem cells of adipose and bone marrow origin. Am. J. Sports Med. 47, 1722–1733 (2019).
Pachler, K. et al. A good manufacturing practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy 19, 458–472 (2017).
Borger, V., Staubach, S., Dittrich, R., Stambouli, O. & Giebel, B. Scaled isolation of mesenchymal stem/stromal cell-derived extracellular vesicles. Curr. Protoc. Stem Cell Biol. 55, e128 (2020).
Nikfarjam, S., Rezaie, J., Zolbanin, N. M. & Jafari, R. Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. J. Transl. Med. 18, 449 (2020).
Monticelli, S. & Natoli, G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat. Immunol. 14, 777–784 (2013).
Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642–649 (2006).
Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392–402 (2013).
Liu, G. Y. et al. Short-term memory of danger signals or environmental stimuli in mesenchymal stem cells: implications for therapeutic potential. Cell Mol. Immunol. 13, 369–378 (2016).
Diez-Tejedor, E. et al. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. J. Stroke Cerebrovasc. Dis. 23, 2694–2700 (2014).
Laskowitz, D. T. et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase I safety study. Stem Cells Transl. Med. 7, 521–529 (2018).
Jeon, S. R. et al. Treatment of spinal cord injury with bone marrow-derived, cultured autologous mesenchymal stem cells. Tissue Eng. Regenerative Med. 7, 316–322 (2010).
Park, J. H. et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery 70, 1238–1247 (2012).
Saito, F. et al. Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study. Restor. Neurol. Neurosci. 30, 127–136 (2012).
El-Kheir, W. A. et al. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transpl. 23, 729–745 (2014).
Karamouzian, S., Nematollahi-Mahani, S. N., Nakhaee, N. & Eskandary, H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin. Neurol. Neurosurg. 114, 935–939 (2012).
Pal, R. et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy 11, 897–911 (2009).
Mendonca, M. V. et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res. Ther. 5, 126 (2014).
Vaquero, J. et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: safety and efficacy of the 100/3 guideline. Cytotherapy 20, 806–819 (2018).
Dai, G. et al. Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res. 1533, 73–79 (2013).
Jiang, P. C. et al. A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury. Exp. Ther. Med. 6, 140–146 (2013).
Jarocha, D., Milczarek, O., Wedrychowicz, A., Kwiatkowski, S. & Majka, M. Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury. Cell Transpl. 24, 661–672 (2015).
Huang, L. et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transpl. 27, 325–334 (2018).
Karussis, D. et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67, 1187–1194 (2010).
Yamout, B. et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J. Neuroimmunol. 227, 185–189 (2010).
Mohajeri, M., Farazmand, A., Mohyeddin Bonab, M., Nikbin, B. & Minagar, A. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iran. J. Allergy Asthma Immunol. 10, 155–161 (2011).
Odinak, M. M. et al. [Transplantation of mesenchymal stem cells in multiple sclerosis]. Zh . Nevrol. Psikhiatr Im. S S Korsakova 111, 72–76 (2011).
Bonab, M. M. et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr. Stem Cell Res Ther. 7, 407–414 (2012).
Mohyeddin Bonab, M. et al. Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Arch. Med Res. 44, 266–272 (2013).
Llufriu, S. et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE 9, e113936 (2014).
Harris, V. K., Vyshkina, T. & Sadiq, S. A. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Cytotherapy 18, 1476–1482 (2016).
Dahbour, S. et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci. Ther. 23, 866–874 (2017).
Meng, M. et al. Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis. Am. J. Transl. Res. 10, 212–223 (2018).
Fernandez, O. et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE 13, e0195891 (2018).
Alvarez-Fuente, M. et al. Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile. Cytotherapy 20, 1337–1344 (2018).
Averyanov, A. et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transl. Med. 9, 6–16 (2020).
Edessy, M. et al. Autologous stem cells therapy, The first baby of idiopathic premature ovarian failure. Acta Med. Int. 3, 19–23 (2016).
Gabr, H., Elkheir, W. & El-Gazzar, A. Autologous stem cell transplantation in patients with idiopathic premature ovarian failure. J. Tissue Sci. Eng. 7, 27 (2016).
Bakhtiary, M. et al. Comparison of transplantation of bone marrow stromal cells (BMSC) and stem cell mobilization by granulocyte colony stimulating factor after traumatic brain injury in rat. Iran. Biomed. J. 14, 142–149 (2010).
Zhou, Z. et al. Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury. Cytotherapy 15, 434–448 (2013).
Yousefifard, M. et al. Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model. Stem Cell Res. Ther. 7, 36 (2016).
Takahashi, A. et al. Comparison of mesenchymal stromal cells isolated from murine adipose tissue and bone marrow in the treatment of spinal cord injury. Cell Transpl. 27, 1126–1139 (2018).
Hao, T. et al. Comparison of bone marrow-vs. adipose tissue-derived mesenchymal stem cells for attenuating liver fibrosis. Exp. Ther. Med. 14, 5956–5964 (2017).
Zare, H., Jamshidi, S., Dehghan, M. M., Saheli, M. & Piryaei, A. Bone marrow or adipose tissue mesenchymal stem cells: Comparison of the therapeutic potentials in mice model of acute liver failure. J. Cell Biochem 119, 5834–5842 (2018).
Arminan, A. et al. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. J. Am. Coll. Cardiol. 55, 2244–2253 (2010).
Gaebel, R. et al. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS ONE 6, e15652 (2011).
Dayan, V. et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res. Cardiol. 106, 1299–1310 (2011).
Lopez, Y. et al. Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. Curr. Stem Cell Res. Ther. 8, 46–59 (2013).
Rasmussen, J. G. et al. Comparison of human adipose-derived stem cells and bone marrow-derived stem cells in a myocardial infarction model. Cell Transpl. 23, 195–206 (2014).
Abd Emami, B. et al. Mechanical and chemical predifferentiation of mesenchymal stem cells into cardiomyocytes and their effectiveness on acute myocardial infarction. Artif. Organs 42, E114–E126 (2018).
Omar, A. M., Meleis, A. E., Arfa, S. A., Zahran, N. M. & Mehanna, R. A. Comparative study of the therapeutic potential of mesenchymal stem cells derived from adipose tissue and bone marrow on acute myocardial infarction model. Oman Med. J. 34, 534–543 (2019).
Wise (formerly TransferWise) is the cheaper, easier way to send money abroad. It helps people move money quickly and easily between bank accounts in different countries. Convert 60+ currencies with ridiculously low fees - on average 7x cheaper than a bank. No hidden fees, no markup on the exchange rate, ever.
How to access the offer?
1- Click here
2- Select “Register''
3- Enter your email address, create a password, and select your country of residence
4- Fill out the required personal information, and the free first transfer offer will be applied automatically.
Benefits of the Multi-Currency Account:
- Free to create online
- Hold 50+ currencies
- Get multiple local bank details in one account (including EU, UK, US)
- Convert currency at the real exchange rate, even on weekends
- Spend whilst travelling on the Wise debit card without high conversion fees
Wise International Transfers:
- $1.5 billion saved by customers every year
- Send money to over 60 target currencies
- Lower fees for larger transfers
- No hidden fees. No bad exchange rates. No surprises.
- Send your money with a bank transfer, or a debit or credit card